Aspire Capital Advisors’s Medtronic MDT Stock Holding History

Aspire Capital Advisors’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,491	Closed	-$216K	–	139
2026 Q1	$216K	Buy	2,491 +197	+9%	+$18.9K	0.05%	114
2025 Q4	$220K	Buy	+2,294	New	+$223K	0.05%	110

Other funds holding MDT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Aspire Capital Advisors's MDT Position: Q2 2026 in Review

Aspire Capital Advisors sold out of Medtronic (MDT) in Q2 2026, closing a stake of 2,491 shares — an estimated $216K sold.

Aspire Capital Advisors first reported a position in MDT in Q4 2025 and held it in 2 quarters. The position peaked at $220K in Q4 2025. 2,128 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

Aspire Capital Advisors reported no remaining Medtronic position as of Q2 2026 after selling out during the quarter.
Aspire Capital Advisors sold 2,491 Medtronic shares in Q2 2026, an estimated $216K.
Aspire Capital Advisors first reported a position in Medtronic in Q4 2025 and held it in 2 quarters.
Aspire Capital Advisors's Medtronic position peaked at $220K in Q4 2025.
2,128 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on Aspire Capital Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.